Colistin use in pediatric intensive care unit for severe nosocomial infections: experience of an university hospital by unknown
Karli et al. Annals of Clinical Microbiology and Antimicrobials 2013, 12:32
http://www.ann-clinmicrob.com/content/12/1/32RESEARCH Open AccessColistin use in pediatric intensive care unit for
severe nosocomial infections: experience of an
university hospital
Arzu Karli1, Muhammet Sukru Paksu2,6*, Adil Karadag3, Nursen Belet1, Sule Paksu4, Akif Koray Guney5,
Muhammet Akgun1, Nazik Yener2 and Sema Gulnar Sensoy1Abstract
Background: The aim of this study was to investigate the efficacy and safety of colistin therapy in pediatric
patients with severe nosocomial infections in pediatric intensive care unit.
Methods: The medical records of patients treated with colistin at a 200-bed university children hospital were
reviewed.
Result: Thirty-one patients (male/female = 22/9; median age, 3 years; range, 3 months-17 years) received forty-one
courses of colistin. The average dose of colistin was 4.9 ± 0.5 mg/kg/day and average treatment duration was 19.8 ±
10.3 days. Three patients who received concomitant nephrotoxic agent with colistin developed nephrotoxicity.
Colistin treatment was well tolerated in other patients, and neurotoxicity was not seen in any patient. Favourable
outcome was achieved in 28 (68.3%) episodes. Twelve patients died during the colistin therapy. Six of these
patients died because of primary underlying disease. The infection-related mortality rate was found 14.6% in this study.
Conclusion: In our study, colistin therapy was found to be acceptable treatment option for the severe pediatric
nosocomial infections caused by multi-drug resistant bacteria. However, the use of concomitant nephrotoxic drugs
with colistin must be avoided and renal function test should be closely monitored.
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Colistin, an antibiotic with a bactericidal effect against
gram-negative bacteria, was introduced for use in the
1950s. However, an abundance of side effects and the
availability of safer alternatives have limited its use [1,2].
Multi-drug resistance (MDR) is defined as the resistance
of microorganisms to at least three different groups of
antibiotics with intrinsic activity against gram-negative
bacteria [3]. Nosocomial infections caused by MDR mi-
croorganisms have been increasing with frequency and
today are a common problem in all areas of the world
[4-6]. The problem of resistance to existing drugs, and
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reproduction in any medium, provided the orin this pharmacologic area, have caused reconsideration
of colistin for use in this context [4,7-9]. Studies on the
efficacy and safety of colistin therapy in children are rare
[4,8,10-12]. This study investigated the efficacy and
safety of colistin therapy in children with severe nosoco-
mial infections in pediatric intensive care unit (PICU).Materials and methods
The study was performed at a PICU of 200-bed univer-
sity children hospital. Forty-one nosocomial infection
episodes that were treated with intravenous colistin and
occurred in thirty-five children between March 2008
and March 2013 were analyzed retrospectively. Neonatal
patients and patients who received colistin treatment for
less than 4 hours were excluded from the study. Informa-
tion recorded included clinical and demographic charac-
teristics, medical history, presence of medical devices such
as central catheters, urinary catheters, and endotracheal or. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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effect neurological or renal systems, clinical and laboratory
findings, type and antimicrobial susceptibility of the iso-
lated microorganism, type of infection that required colis-
tin treatment (bloodstream infection, ventilator-associated
pneumonia, etc.), dose, administration route, dur-
ation and side effects of colistin, results of antimicro-
bial therapy, and prognosis. The levels of blood urea
nitrogen (BUN), creatinine, C-reactive protein (CRP)
and the counts of leukocytes and platelets were re-
corded (at the beginning and during treatment). Clinical
and laboratory data were obtained from patients’ cards
and from the hospital computer database system.
Pediatric risk of mortality (PRISM) and pediatric logic
organ dysfunction (PELOD) scores were used to deter-
mine the severity of illness and organ dysfunction re-
spectively. The medical records of each patient were
investigated also for signs of neurotoxicity (neuromus-
cular blockade, seizures, change in level of conscious-
ness, etc.) during treatment.
The diagnosis of infection was made by clinical and
laboratory findings and through positive culture. The
diagnosis of nosocomial infection and specific infec-
tions such as catheter-related infection, ventilator-as-
sociated pneumonia (VAP) was made on the basis of
the criteria of the Centers for Disease Control and
Prevention [13]; sepsis was defined according to the defin-
ition of the International Pediatric Sepsis Consensus Con-
ference [14].
Some of the important terms used in this paper were
defined as follows: Multi-drug resistance was defined as
the resistance of microorganisms to at least three differ-
ent groups of antibiotics with intrinsic activity against
gram-negative bacteria (e.g., beta-lactams, aminoglyco-
sides, carbapenems, and quinolones) [3]. Empirical treat-
ment was defined as the beginning of colistin treatment
based on surveillance data, or on inadequate response of
the infection to other antimicrobials [10]. Response to
treatment was defined as improved clinical and labora-
tory findings of index infection, and eradication of the
pathogen microorganism isolated by initial culture. If
the patient was alive at the end of treatment, prognosis
was evaluated as a survey. Patients who died during
treatment were also assessed in order to find out if the
death had been caused by infection. Nephrotoxicity was
defined in patients with normal baseline renal functions
as serum creatinine levels higher than >1.1 mg/dl, or by
a >50% reduction in creatinine clearance or by the need
for renal replacement treatment (RRT) at any time dur-
ing treatment.
Descriptive statistics were used in the data analysis.
The study was approved by the Ondokuz Mayis Uni-
versitiy Human Studies Ethics committee. (No:2011/
2062)Results
In this study 41 nosocomial infection episodes treated
by iv colistin in 35 pediatric patients were reviewed. Six
patients had two episodes. Four patients who received
colistin treatment for less than 48 hours were not in-
cluded in the study. The median age of patients was
3 years (range, 3 month-17 years). Five (14.3%) patients
had been previously healthy; the other patients had an
underlying chronic disease. Underlying diseases, in order
of frequency, were as follows; neurological/neuromuscular
disorders (28.6%), congenital heart disease (22.9%), inher-
ited metabolic disorders (14.3%), primary immune defi-
ciency (11.4%), malignancy (2.9%) and others (5.7%).
When colistin therapy started, all patients except for
one were on ventilation. The clinical and demographic
characteristics of study patients were shown in Table 1.
In 5 patients, intravenous colistin therapy was started
empirically because of fever that was unresponsive to
broad-spectrum antimicrobial treatment and progressive
sepsis. In other patients, indication of colistin treatment
was culture-proven infection. The most frequently isolated
microorganism, the most common isolation site and type
of infections were A. baumannii, tracheal aspirate, and
VAP respectively.
The microorganisms were isolated from a single site in
58.3% of the culture-proven cases and from more than
one site in 41.7%. All of the patients had received anti-
microbial treatment in different combinations before
and during colistin treatment. The drugs which effective
against gram negative bacteria most frequently used with
colistin were carbapenems and aminoglycosides in order
of frequency. The properties of nosocomial infections
treated by colistin and isolated microorganisms were
shown in Table 2.
Colistin was administered intravenously in all patients;
none of the patients received concomitant nebulized
treatment. Only one patient had received intrathecal
treatment in addition to iv route due to shunt infection.
Due to impaired renal function, dosage adjustment was
made in three patients at the beginning of treatment and
in one patient during treatment. The average dose of co-
listin was 4.90 ± 0.5 mg/kg/day in patients without renal
impairment, and considering all the episodes, the aver-
age duration of treatment was 19.8 ± 10.3 days (surviving
patients 23.1 ± 10.0, non-surviving patients 11.8 ± 5.6).
Dose, duration, and side effects of colistin, and treat-
ment results were shown in Table 3.
Renal replacement therapy and dose-adjusted colistin
were started in three patients who had renal insufficiency
before the colistin therapy. One of these patients had
chronic renal failure and was on dialysis treatment. The
other two patients had renal impairment as a component
of multiorgan failure. While a single hemodialysis session
(P4) was performed in one of these patients, the other
Table 1 Demographic and clinical characteristics of study patients
Age (month) [median (minimum-maximum)] 36 (3–204)
Male gender [number (%)] 22 (%62.9)
Weight (kg) [median (minimum-maximum)] 12 (3–70)
Comorbidity [number (%)] 30 (85.7%)
● Chronic neurological or neuromuscular disorders 10 (28.6%)
● Congenital heart disease 8 (2.9%)
● Inherited metabolic disorders 5 (14.3%)
● Primary immune deficiency 4 (11.4%)
● Malignancy 1 (2.9%)
● Others 2 (5.7%)
Immune deficiency [number (%)] 9 (%25.7)
● Primary immune deficiency 2
● Immunosuppressive treatment 7
Cause of PICU admission
● Respiratory failure 21 (%60.0)
● Acute loss of consciousness, CNS infections or status epilepticus 6 (%17.1)
● Post-operative follow-up or complications 4 (%11.4)
● Sepsis or shock 3 (%8.6)
● Poisoning 1 (%2.9)
Length of stay in PICU before infection (day) [median (min-max)] 30 (0–126)
Total length of stay in hospital before infection (day) [median (min-max)] 39 (0–142)
Duration of mechanical ventilation (day) [median (min-max)] 25 (0–108)
Medical devices (existed at the beginning of colistin treatment)
● Endotracheal or tracheostomy tube 41 (100%)
● Central venous or arterial catheter 33 (80.5%)
● Foley catheter 30(73.2%)
● Thorax tube 2 (4.9%)
● External ventricular drainage catheter 2 (4.9%)
● Peritoneal dialysis catheter 1 (2.4%)
PRISM score at admission of PICU 18.4 ± 9.2
PELOD score at the start of colistin treatment 16.2 ± 9.7
Organ failure at the start of colistin treatment
● Neurological 30 (73.2%)
● Respiratory 40 (97.6%)
● Cardiac 12 (29.3%)
● Renal 3 (7.3%)
● Hepatic 2 (4.9%)
● Hematologic None
PRISM: Pediatric Risk of Mortality, PELOD: Pediatric Logistik Organ Dysfunction.
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acteristics of the patients with renal impairment at the
beginning of or during therapy were given in Table 4.
Only three of thirty-four episode used concomitant
nephrotoxic agent with colistin developed renal impair-
ment. All three of these patients received at least one
nephrotoxic agent such as aminoglycosides, amphotericinB or a glycopeptides together with colistin. In patient
8, peritoneal dialysis was started after 13 days of colis-
tin treatment because of oliguric renal failure and
remained for 14 days. Gentamicin treatment was dis-
continued and doses of colistin were adjusted accord-
ing to the creatinin clearance in this patient. Level of
creatinine was 5.6 mg/dl at the end of 22 days of
Table 2 Properties of nosocomial infections treated by
colistin and causative microorganisms
Indications of colistin treatment (%)]
● Culture-proven infection 36 (87.8%)
● Empirically 5 (12.2%)
Causative microorganism [number (%)]
● A. baumannii 20 (48.8%)
● P. aeruginosa 9 (22.0%)
● A. baumannii and P. aeruginosa 7 (17.1%)
● No microorganism 5 (12.2%)
Isolation sites of the microorganisms
● Tracheal aspirate fluid 24 (58.5%)
● Blood or central venous catheter tip 19 (46.3%)
● Skin swabs, conjunctival swabs 4 (9.8%)
● Cerebrospinal fluid 2 (4.9%)
Concomitant antimicrobial agent effective against
gram negatives used with colistin [number (%)]
● Carbapenems 22 (53.7%)
● Aminoglycosides 14 (34.1%)
● Piperacillin-tazobactam 5 (12.2%)
● Cefoperazone-sulbactam 1 (2.4%)
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after the end of treatment. Acute renal failure devel-
oped after eight days of treatment in patient 12. Colis-
tin treatment was discontinued and bloodstream
infection caused by P. aeruginosa was treated success-
fully with meropenem in this patient despite in-vitro
resistance. In patient 15 who had ataxia telengiectasia,
non-oliguric renal failure developed on the fourth day
of colistin treatment due to severe sepsis and septic
shock. Colistin was continued in this patient because
of severe sepsis and immune deficiency. The patient
died on the eighth day of treatment before RRT was
performed. Possible cause of renal failure in this pa-
tient was refractory shock and multiorgan dysfunction
syndrome. We did not find neurological side-effects
(change of consciousness, seizures, visual disturbances,
or neuromuscular blockade) in any patients. However,
most of the patients were comatose or were receiving
sedative-analgesic agent.
In twenty-eight (68.3%) episodes, positive clinical re-
sponse was achieved. Twelve patients died while receiv-
ing colistin therapy. Six of these patients died because
of infection-related reasons, and others died of primary
underlying disease. Renal impairment was developed in
one patient who died due to infection-related reasons;
however, RRT was not performed due to sufficient urine
output. Positive clinical and microbiological results
were obtained in other patients (Table 3).Discussion
Nosocomial infections caused by multidrug-resistant gram-
negative microorganisms are an important cause of mor-
bidity and mortality in intensive care units [15,16]. We
previously reported the results of a multicenter study in-
vestigating the efficacy and safety of colistin treatment in
PICU [12]. In this study we aimed to present our experi-
ence about the use of colistin in severe nosocomial infec-
tions in our PICU during a longer period of time and with
newly emerged patients.
A few studies have investigated the efficacy and safety
of colistin therapy in children thus far, and the majority
of existing studies have been performed in specific pa-
tient groups such as newborns and patients with cystic
fibrosis or burn injuries [4,11,17]. No special patient
group was singled out in our study, differentiating it
from previous studies. The results of present study have
suggests that colistin may be a viable option in the treat-
ment of serious pediatric nosocomial infections caused
by MDR gram-negative bacteria.
The optimum pediatric dosing for colistin is not clear
due to lack of the pharmacokinetic and pharmacodynamic
studies in this age group. However, an intravenous dose of
2.5-5 mg/kg/day has been recommended [2,4,11,18]. In
our study we found the average dose of 4.9 mg/kg/day
divided into 2 or 3 equal doses effective and safe.
The major side effects of treatment with colistin are
neurotoxicity and nephrotoxicity [4,8,11,12,19]. Recent
pediatric studies have reported a nephrotoxicity rate of
0–14.3% [4,8,10-12,18]. This rate is lower than that given in
previously reported results in adults (5.8-26.8%) [20-22].
The main mechanism of renal injury is acute tubular
necrosis. Renal injury usually occurs in the early stages
of treatment and characterized by a decrease in creatin-
ine clearance and increase in serum urea and creatinine
levels [2,17]. In our study renal toxicity occurred at the
median 8th day of treatment (relatively late). Less com-
monly, hematuria, proteinuria, and cylindruria may also
be seen [17]. Similar to our study sepsis, hypotension
and the use of other nephrotoxic drugs due to nosocomial
infections may potentiate the nephrotoxicty of colistin
[4,10,12,17]. Many studies have reported that the use of
other nephrotoxic drugs such as aminoglycosides together
with colistin facilitates the deterioration of renal function
[4,10,12,17,23-26]. In our study colistin was used with
other nephrotoxic agents such as aminoglycoside, vanco-
micyn or amphotericin B in twenty-nine of forty-one epi-
sodes of nosocomial infection and only three patients
developed nephrotoxicity. Similarly, Jajoo and colleagues
[17] reported that nephrotoxicity occured in only one of
six newborns after the administration of netilmicin. Inter-
estingly, Li and colleagues [25] reported that colistin is less
nephrotoxic than amikacin or tobramycin. Both adult and
pediatric studies have reported that the nephrotoxicity of
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*Infection-related death, **Infection-unrelated death, BUN: Blood urea nitrogen, RI: Renal impairment, RRT: Renal replacement therapy, ARF: Acute renal failure,
CRF: Chronic renal failure.
Table 3 Dose, duration, and side effects of colistin, and treatment results
Dose in patients without renal failure (mg/kg) 4.90 ± 0.5
Duration (day) 19.8 ± 10.3 (4–62)
● Favorable outcome 23.1 ± 10.0 (8–62)
● Poor outcome or discontinuation of therapy 11.8 ± 5.6 (4–22)
Side effects (renal function impairment) 3 (7.3%)
Using of sedative or analgesic agents during the colistin treatment 28 (68.3%)
Concomitants nephrotoxic agent use 34 (82.9%)
Common nephrotoxic agents used with colistin
● Glycopeptides 23 (56.1%)
● Aminoglycosides 14 (34.1%)
● Furosemide 11 (26.8%)
● Amphotericin B 10 (24.4%)
● Antiviral agent (acyclovir) 1 (2.4%)
● Radiocontrast 1 (2.4%)
Result of treatment:
● Survey 29 (70.7%)
○ Clinical and microbiological response 28
○ Discontinuation of treatment due to side effect 1
● Exitus 12 (29.3%)
○ Infection related death 6
○ Infection unrelated death 6
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with discontinuation of treatment [2,8,19]. In our study
treatment with gentamicin was halted in one patient be-
cause of nephrotoxicity, but colistin therapy was contin-
ued due to life-threatening sepsis. With peritoneal dialysis,
renal function returned to normal levels 18 days after the
end of colistin treatment in this patient. In other patient,
colistin treatment was changed with meropenem and
renal function returned to normal levels within days. In
our unit, none of the patiens used colistin developed nefh-
rotoxicity in the last two years. None of the patient used
colistin in the last two years developed nephrotoxicity. We
attribute this to the increased sensitivity of our team re-
garding renal toxicity, to closer monitoring of fluid balance
and renal functions in colistin users, and to the avoidance
of the use of concomitant nephrotoxic agents.
There are very few reported neurological side effects of
colsitin in pediatric studies [8,11,12,17], and neurological
side effects were not observed in our study. The challenge
of detecting neurological side effects in patients with
underlying neurological disease may be the reason for this.
Other possible reasons include the fact that drugs fre-
quently used in the intensive care unit (such as sedative/
analgesic drugs, or neuromuscular blocking agents) can
mask neurological side effects and neurological side effects
may also be overlooked in retrospective studies. Finally,
the use of sodium colistimethate (which is less toxic than
colistin) in our study may be another reason for the lack
of neurological side effects [8,16].
Favorable clinical response rates have reportedly been
higher in pediatric studies than in adult studies (76–86.5%
versus 57-73%, respectively) [8-10,20,27]. A favorable
outcome occurred in 68.3% courses and was consistent
with the previous studies. In addition, positive clinical
and microbiological response was achieved in 6 out of 7
episodes developed in 4 patients with primary immune
deficiency.
The synergistic effect of concomitant use of colistin
with rifampicin, carbapenems, piperacillin/tazobactam,
or ciprofloxacin has been reported in previous studies
[24,25,28-32]. Similar to previous studies, we used colis-
tin in various combinations with other antimicrobial
agents. In this study, colistin was combined with an anti-
biotic against on gram-negative bacteria in almost all
cases. We believe that combination regimen can contrib-
ute to the success rate of treatment.
Prognosis in the case of a bacterial infection caused by
MDR is affected by the presence of underlying disease,
sepsis, or organ failure. Of the 35 patients in our study,
30 had underlying chronic diseases and 4 had immuno-
deficiency. A mortality rate of 2-28% has been reported
in previous studies [8,11,12,17]. Our results are similar
to previous reports. While 6 out of the 12 patients who
died during the study period died of infection-relatedreasons, the others died because of their primary diseases
such as multiple trauma, malignancy and congenital heart
diseases.
The major limitations of this study include the retro-
spective design and the insufficient number of patients
which is too limited to determine the true incidence of
drug-related side effects. Additionally, patients had taken
many drugs before and during treatment with colistin.
Therefore, it was not possible to associate all the effects
and side effects that occurred during the study with
colistin alone.
In conclusion, the results of this study have shown
that colistin is effective in the treatment of serious
nosocomial infections caused by MDR gram-negative
bacteria in children. Renal function test must be closely
monitored during the treatment period. We suggest
avoiding the use of other nephrotoxic drugs with colistin
to minimize the nephrotoxicity. However, more prospect-
ive controlled trials are needed to objectively evaluate the
efficacy and side effects of this treatment.
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